257 related articles for article (PubMed ID: 29110061)
1. The impact of GI events on persistence and adherence to osteoporosis treatment: 3-, 6-, and 12-month findings in the MUSIC-OS study.
Modi A; Sen S; Adachi JD; Adami S; Cortet B; Cooper AL; Geusens P; Mellström D; Weaver JP; van den Bergh JP; Keown P; Sajjan S
Osteoporos Int; 2018 Feb; 29(2):329-337. PubMed ID: 29110061
[TBL] [Abstract][Full Text] [Related]
2. Gastrointestinal symptoms and association with medication use patterns, adherence, treatment satisfaction, quality of life, and resource use in osteoporosis: baseline results of the MUSIC-OS study.
Modi A; Sen S; Adachi JD; Adami S; Cortet B; Cooper AL; Geusens P; Mellström D; Weaver J; van den Bergh JP; Nguyen AM; Sajjan S;
Osteoporos Int; 2016 Mar; 27(3):1227-1238. PubMed ID: 26637321
[TBL] [Abstract][Full Text] [Related]
3. Impact of gastrointestinal events on patient-reported outcomes in Asia-Pacific women with osteoporosis: baseline results of the MUSIC OS-AP study.
Modi A; Ebeling PR; Lee MS; Min YK; Mithal A; Yang X; Baidya S; Sen S; Sajjan S
Arch Osteoporos; 2017 Dec; 12(1):65. PubMed ID: 28718004
[TBL] [Abstract][Full Text] [Related]
4. Association of gastrointestinal events with quality of life and treatment satisfaction in osteoporosis patients: results from the Medication Use Patterns, Treatment Satisfaction, and Inadequate Control of Osteoporosis Study (MUSIC OS).
Modi A; Sen S; Adachi JD; Adami S; Cortet B; Cooper AL; Geusens P; Mellström D; Weaver JP; van den Bergh JP; Keown PA; Sajjan S
Osteoporos Int; 2017 Oct; 28(10):2867-2876. PubMed ID: 28643048
[TBL] [Abstract][Full Text] [Related]
5. Rationale and design of MUSIC OS-EU: an international observational study of the treatment of postmenopausal women for osteoporosis in Europe and Canada.
Modi A; Sen S; Adachi JD; Adami S; Cortet B; Cooper AL; Geusens P; Mellström D; Weaver JP; van den Bergh JP; Nguyen AM; Keown PA; Leung AT; Sajjan S
Clin Exp Rheumatol; 2015; 33(4):537-44. PubMed ID: 26146786
[TBL] [Abstract][Full Text] [Related]
6. Persistence, adherence, and medication-taking behavior in women with postmenopausal osteoporosis receiving denosumab in routine practice in Germany, Austria, Greece, and Belgium: 12-month results from a European non-interventional study.
Hadji P; Papaioannou N; Gielen E; Feudjo Tepie M; Zhang E; Frieling I; Geusens P; Makras P; Resch H; Möller G; Kalouche-Khalil L; Fahrleitner-Pammer A
Osteoporos Int; 2015 Oct; 26(10):2479-89. PubMed ID: 26018090
[TBL] [Abstract][Full Text] [Related]
7. Factors associated with high 24-month persistence with denosumab: results of a real-world, non-interventional study of women with postmenopausal osteoporosis in Germany, Austria, Greece, and Belgium.
Fahrleitner-Pammer A; Papaioannou N; Gielen E; Feudjo Tepie M; Toffis C; Frieling I; Geusens P; Makras P; Boschitsch E; Callens J; Anastasilakis AD; Niedhart C; Resch H; Kalouche-Khalil L; Hadji P
Arch Osteoporos; 2017 Dec; 12(1):58. PubMed ID: 28643265
[TBL] [Abstract][Full Text] [Related]
8. Persistence at 12 months with denosumab in postmenopausal women with osteoporosis: interim results from a prospective observational study.
Silverman SL; Siris E; Kendler DL; Belazi D; Brown JP; Gold DT; Lewiecki EM; Papaioannou A; Simonelli C; Ferreira I; Balasubramanian A; Dakin P; Ho P; Siddhanti S; Stolshek B; Recknor C
Osteoporos Int; 2015 Jan; 26(1):361-72. PubMed ID: 25236877
[TBL] [Abstract][Full Text] [Related]
9. Association between gastrointestinal events and persistence with osteoporosis therapy: analysis of administrative claims of a U.S. managed care population.
Modi A; Siris S; Yang X; Fan CP; Sajjan S
J Manag Care Spec Pharm; 2015 Jun; 21(6):499-506. PubMed ID: 26011551
[TBL] [Abstract][Full Text] [Related]
10. Medication Use Patterns, Treatment Satisfaction, and Inadequate Control of Osteoporosis Study in the Asia-Pacific Region (MUSIC OS-AP): Design of a multinational, prospective, observational study examining the impact of gastrointestinal events on osteoporosis management in postmenopausal women.
Modi A; Ebeling PR; Lee MS; Min YK; Mithal A; Yang X; Sajjan S
Bone Rep; 2015 Dec; 3():61-66. PubMed ID: 28377968
[TBL] [Abstract][Full Text] [Related]
11. The non-interventional BonViva Intravenous Versus Alendronate (VIVA) study: real-world adherence and persistence to medication, efficacy, and safety, in patients with postmenopausal osteoporosis.
Hadji P; Felsenberg D; Amling M; Hofbauer LC; Kandenwein JA; Kurth A
Osteoporos Int; 2014 Jan; 25(1):339-47. PubMed ID: 24091594
[TBL] [Abstract][Full Text] [Related]
12. Gastrointestinal side effects in postmenopausal women using osteoporosis therapy: 1-year findings in the POSSIBLE US study.
Woo C; Gao G; Wade S; Hochberg MC
Curr Med Res Opin; 2010 Apr; 26(4):1003-9. PubMed ID: 20201623
[TBL] [Abstract][Full Text] [Related]
13. Adherence to and gastrointestinal tolerability of monthly oral or quarterly intravenous ibandronate therapy in women with previous intolerance to oral bisphosphonates: a 12-month, open-label, prospective evaluation.
Lewiecki EM; Babbitt AM; Piziak VK; Ozturk ZE; Bone HG
Clin Ther; 2008 Apr; 30(4):605-21. PubMed ID: 18498910
[TBL] [Abstract][Full Text] [Related]
14. Assessment of patient-reported outcomes (PROs): treatment satisfaction, medication adherence, and quality of life (QoL) and the associated factors in postmenopausal osteoporosis (PMO) patients in Korea.
Byun DW; Moon SH; Kim T; Lee HH; Park HM; Kang MI; Ha YC; Chung HY; Yoon BK; Kim TY; Chae SU; Shin CS; Yang KH; Lee JH; Chang JS; Kim SH; Kim IJ; Koh JM; Jung JH; Yi KW; Yoo JJ; Chung DJ; Lee YK; Yoon HK; Hong S; Kim DY; Baek KH; Kim HJ; Kim YJ; Kang S; Min YK
J Bone Miner Metab; 2019 May; 37(3):563-572. PubMed ID: 30238428
[TBL] [Abstract][Full Text] [Related]
15. GRAND: the German retrospective cohort analysis on compliance and persistence and the associated risk of fractures in osteoporotic women treated with oral bisphosphonates.
Hadji P; Claus V; Ziller V; Intorcia M; Kostev K; Steinle T
Osteoporos Int; 2012 Jan; 23(1):223-31. PubMed ID: 21308365
[TBL] [Abstract][Full Text] [Related]
16. Marginal structural model to evaluate the association between cumulative osteoporosis medication and infection using claims data.
Xue F; Goli V; Petraro P; McMullan T; Sprafka JM; Tchetgen Tchetgen EJ
Osteoporos Int; 2017 Oct; 28(10):2893-2901. PubMed ID: 28685279
[TBL] [Abstract][Full Text] [Related]
17. Undertreatment of osteoporosis and the role of gastrointestinal events among elderly osteoporotic women with Medicare Part D drug coverage.
Siris ES; Yu J; Bognar K; DeKoven M; Shrestha A; Romley JA; Modi A
Clin Interv Aging; 2015; 10():1813-24. PubMed ID: 26604724
[TBL] [Abstract][Full Text] [Related]
18. Retrospective evaluation of persistence in osteoporosis therapy with oral bisphosphonates in Italy: the TOBI study.
Gonnelli S; Caffarelli C; Letizia Mauro G; Di Munno O; Malavolta N; Migliaccio S; Nuti R
Aging Clin Exp Res; 2019 Nov; 31(11):1541-1547. PubMed ID: 31030419
[TBL] [Abstract][Full Text] [Related]
19. Persistence at 24 months with denosumab among postmenopausal women with osteoporosis: results of a prospective cohort study.
Silverman SL; Siris E; Belazi D; Recknor C; Papaioannou A; Brown JP; Gold DT; Lewiecki EM; Quinn G; Balasubramanian A; Yue S; Stolshek B; Kendler DL
Arch Osteoporos; 2018 Aug; 13(1):85. PubMed ID: 30088189
[TBL] [Abstract][Full Text] [Related]
20. Association of gastrointestinal events and osteoporosis treatment initiation in newly diagnosed osteoporotic Israeli women.
Yu J; Goldshtein I; Shalev V; Chodick G; Ish-Shalom S; Sharon O; Modi A
Int J Clin Pract; 2015 Sep; 69(9):1007-14. PubMed ID: 26278464
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
